TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19837318

Group type: EXPERIMENTAL
Intervention: PES split crest implants
Number of subjects: 86

Group type: COMPARATOR
Intervention: unsplit alveolar ridge implants
Number of subjects: 86
Study: 17023212

Group type: EXPERIMENTAL
Intervention: Acupuncture (n=12), received once a week for 10 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham acupuncture (n=12), needle insertion in non-acupoints, received once a week for 10 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (n=12), receiving no treatment
Number of subjects: 36
Study: 14995941

Group type: EXPERIMENTAL
Intervention: Lung Recruitment Maneuver (LRM) - four 10‐s insufflations to an airway pressure of 45 cmH2O
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PEEP 12 cmH2O
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lung Recruitment Maneuver + PEEP 12 cmH2O
Number of subjects: 30
Study: 11240413

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9825375

Group type: EXPERIMENTAL
Intervention: 2 Fr electrode catheters
Number of subjects: 205

Group type: COMPARATOR
Intervention: 6 Fr electrode catheters
Number of subjects: 205
Study: 7719108

Group type: EXPERIMENTAL
Intervention: Large doses of hyoscyamus, self made Retarded Recovery Pill and acupuncture
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nao An Tai, Nao Fu Kang (Control)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combined therapy of traditional Chinese and Western medicine
Number of subjects: 80
Study: 2643074

Group type: EXPERIMENTAL
Intervention: Dexamethasone (3 tablets of 4 mg each)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dextrose placebo (identical in appearance, same dosage schedule)
Number of subjects: 40
Study: 4553613

Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 380

Group type: COMPARATOR
Intervention: Control
Number of subjects: 380
Study: 31883336

Group type: EXPERIMENTAL
Intervention: WebQuit Plus (ACT-based intervention)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Smokefree.gov (control)
Number of subjects: 51
Study: 31405866

Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g) plus piperaquine (960 mg) for three days
Number of subjects: 122

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (4,500 mg sulfadoxine plus 225 mg pyrimethamine, single dose)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Azithromycin plus piperaquine
Number of subjects: 122

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 122
Study: 29017627

Group type: COMPARATOR
Intervention: 20 g milk protein (MLK20)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 g mycoprotein (MYC20)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 40 g mycoprotein (MYC40)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 60 g mycoprotein (MYC60)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 80 g mycoprotein (MYC80)
Number of subjects: 12
Study: 25622774

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading, 90 mg twice daily for maintenance dose)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Clopidogrel (300 mg loading, 75 mg once daily for maintenance dose)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 25
Study: 23179117

Group type: COMPARATOR
Intervention: Ropivacaine 0.25% alone on the brachial plexus nerve (Group A)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25% with 20 mg parecoxib locally on the nerve block (Group B)
Number of subjects: 150

Group type: COMPARATOR
Intervention: 20 mg parecoxib intravenously (Group C)
Number of subjects: 150
Study: 21351829

Group type: EXPERIMENTAL
Intervention: Maximal doses of 20 Gy delivered by the X‐knife unit 16 days postimplantation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Tumor group (control)
Number of subjects: 25
Study: 19114383

Group type: EXPERIMENTAL
Intervention: Smoke|Quit
Number of subjects: 216

Group type: COMPARATOR
Intervention: Canadian Cancer Society's self-help program
Number of subjects: 216

Group type: COMPARATOR
Intervention: Usual care quit kit
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 216
Study: 16995861

Group type: EXPERIMENTAL
Intervention: 200 microg salbutamol via pMDI + Volumatic
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 400 microg salbutamol via pMDI + Volumatic
Number of subjects: 18

Group type: COMPARATOR
Intervention: 558 microg salbutamol via Diskus
Number of subjects: 18

Group type: COMPARATOR
Intervention: 395 microg salbutamol via Diskus
Number of subjects: 18

Group type: COMPARATOR
Intervention: 404 microg salbutamol via Diskus
Number of subjects: 18
Study: 15560538

Group type: EXPERIMENTAL
Intervention: Bisoprolol (5 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11129616

Group type: EXPERIMENTAL
Intervention: Ephedrine (70 micrograms.kg‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30
Study: 9285655

Group type: EXPERIMENTAL
Intervention: Early initiation of ramipril (24 hours after AMI)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Delayed initiation of ramipril (14 days after AMI)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Follow-up after AMI
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Patients with thrombus
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: LV size
Number of subjects: 309
Study: 8367518

Group type: EXPERIMENTAL
Intervention: Constrained least-squares restoration (CLSR) technique
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Model based on renography parameters (excretion ratio, rate of uptake, time to peak activity)
Number of subjects: 70
Study: 6761832

Group type: EXPERIMENTAL
Intervention: Flunisolide 50 micrograms in each nostril twice daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate 50 micrograms in each nostril four times daily
Number of subjects: 47
Study: 31747663

Group type: EXPERIMENTAL
Intervention: Ranibizumab (RBZ)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normal eyes (control group)
Number of subjects: 25
Study: 31348973

Group type: EXPERIMENTAL
Intervention: Responsive feeding style (adapting feeding pace to spoonful weight)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Infants' appetitive traits (food responsiveness)
Number of subjects: 38
Study: 28454194

Group type: EXPERIMENTAL
Intervention: Operative treatment (arthroscopy of the shoulder)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conservative treatment (physiotherapy under physician control)
Number of subjects: 86
Study: 25875938

Group type: EXPERIMENTAL
Intervention: Laughter therapy (3 sessions, 60 minutes each)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 62
Study: 24332581

Group type: EXPERIMENTAL
Intervention: EBRT (external beam whole breast radiotherapy)
Number of subjects: 141

Group type: COMPARATOR
Intervention: IORT (intraoperative radiotherapy)
Number of subjects: 141
Study: 22997185

Group type: EXPERIMENTAL
Intervention: Dark chocolate bars (35% fat)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Chocolate dessert (8% fat)
Number of subjects: 8
Study: 19204263

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 20 mg p.o. with interferon beta‐1a
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: IV methylprednisolone (IVMP) 1,000 mg/day for 3 days bimonthly with interferon beta‐1a
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo with interferon beta‐1a
Number of subjects: 313
Study: 17324291

Group type: EXPERIMENTAL
Intervention: Neck manipulation
Number of subjects: 182

Group type: COMPARATOR
Intervention: Neck mobilisation
Number of subjects: 182
Study: 16098943

Group type: EXPERIMENTAL
Intervention: Corpus-based measures of word semantics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual world paradigm
Number of subjects: 0
Study: 14553868

Group type: EXPERIMENTAL
Intervention: Practice guideline implemented using a multifaceted strategy
Number of subjects: 608

Group type: COMPARATOR
Intervention: Practice guideline alone (control arm)
Number of subjects: 608
Study: 10584043

Group type: EXPERIMENTAL
Intervention: Average American Diet (AAD: 34.3% total fat, 15.0% saturated fat)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: American Heart Association Step I diet (28.6% total fat, 9.0% saturated fat)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Low-fat diet (25.3% total fat, 6.1% saturated fat)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Average American Diet (AAD)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: American Heart Association Step I diet
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Diet-induced changes in serum triacylglycerol
Number of subjects: 103
Study: 9005824

Group type: EXPERIMENTAL
Intervention: Destructive changes in B-cells
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Sclerosis and hyalinosis of vascular wall
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Langerhans islands sclerosis
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Normal structure of the acinar compartment of the pancreas
Number of subjects: 49
Study: 2015167

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hydralazine
Number of subjects: 50
Study: 6688538

Group type: EXPERIMENTAL
Intervention: CAF (cyclophosphamide, doxorubicin, and 5-fluorouracil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CAF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adriamycin-containing combinations
Number of subjects: 0
Study: 31046165

Group type: EXPERIMENTAL
Intervention: Day clinic (DC) management model
Number of subjects: 470

Group type: COMPARATOR
Intervention: Hospital inpatient care
Number of subjects: 470
Study: 28257940

Group type: EXPERIMENTAL
Intervention: Acceptance-based behavioral treatment (ABT)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Standard behavioral treatment (SBT)
Number of subjects: 190
Study: 25743263

Group type: EXPERIMENTAL
Intervention: Pasireotide (600-1200 µg bid for at least 6 months)
Number of subjects: 8
Study: 23530172

Group type: EXPERIMENTAL
Intervention: Spontaneously descended testis
Number of subjects: 91

Group type: COMPARATOR
Intervention: Boys operated on at 3 years
Number of subjects: 91

Group type: COMPARATOR
Intervention: Boys operated on at 9 months
Number of subjects: 91
Study: 21696245

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (LNS), a peanut-based micronutrient fortified paste
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Weaning strategies (including gradual reduction of breast-feeding, expressing breast-milk into a cup, and separation of mother and child)
Number of subjects: 45
Study: 19783896

Group type: EXPERIMENTAL
Intervention: 10 mg of atorvastatin plus 10 mg of ezetimibe
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 80 mg of atorvastatin
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 10 mg of atorvastatin plus 10 mg of ezetimibe (after crossover)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 80 mg of atorvastatin (initially)
Number of subjects: 98
Study: 16432273

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (Ginkgold, 3 doses of 120 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 12543214

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo mixture (nutritionally balanced amino acid mixture containing tryptophan)
Number of subjects: 18
Study: 11351835

Group type: EXPERIMENTAL
Intervention: Frequent pornography use, particularly violent pornography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Men at high risk for sexual aggression
Number of subjects: 0
Study: 9432291

Group type: EXPERIMENTAL
Intervention: Fluvastatin (Lescol, Sandoz Pharma Ltd) 20 mg once daily, increased to 40 mg if LDL‐Ch > 3.5 mmol/l
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group on low fat and low cholesterol diet
Number of subjects: 62
Study: 1528206

Group type: EXPERIMENTAL
Intervention: Caffeine (equal to daily caffeine consumption)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 3880874

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31711422

Group type: EXPERIMENTAL
Intervention: Hypoxic preconditioning (HPC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 29777823

Group type: EXPERIMENTAL
Intervention: Atezolizumab, 1200 mg, intravenously every 3 weeks
Number of subjects: 2075

Group type: COMPARATOR
Intervention: Docetaxel, 75 mg/m2, intravenously every 3 weeks
Number of subjects: 2075
Study: 27105870

Group type: EXPERIMENTAL
Intervention: EPA-rich triglyceride concentrates (3.1 g EPA/d)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: DHA-rich triglyceride concentrates (2.9 g DHA/d)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Refined olive oil (placebo)
Number of subjects: 48
Study: 25295645

Group type: EXPERIMENTAL
Intervention: MDX 1400 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: MDX 700 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 22537617

Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye 0.5 mg every 4 weeks (0.5q4)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye 2 mg every 4 weeks (2q4)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye 2 mg every 8 weeks after 3 initial monthly doses (2q8)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye 2 mg as needed after 3 initial monthly doses (2PRN)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Laser photocoagulation
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye groups (combined)
Number of subjects: 221
Study: 20168206

Group type: EXPERIMENTAL
Intervention: Circumcised men
Number of subjects: 4889

Group type: COMPARATOR
Intervention: Uncircumcised men
Number of subjects: 4889

Group type: EXPERIMENTAL
Intervention: Unprotected insertive anal sex with HIV-positive partner
Number of subjects: 4889

Group type: EXPERIMENTAL
Intervention: Unprotected receptive anal sex with HIV-positive partner
Number of subjects: 4889

Group type: EXPERIMENTAL
Intervention: Interaction of being uncircumcised and unprotected insertive anal sex
Number of subjects: 4889

Group type: EXPERIMENTAL
Intervention: Interaction of being uncircumcised and unprotected receptive anal sex
Number of subjects: 4889

Group type: EXPERIMENTAL
Intervention: Circumcision status
Number of subjects: 4889
Study: 17698601

Group type: EXPERIMENTAL
Intervention: Postoperative pain
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Baseline anxiety
Number of subjects: 139
Study: 16213930

Group type: EXPERIMENTAL
Intervention: Azithromycin (12 mg/kg on days 1-5, repeated on days 11-15 and days 21-25)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (administered in the same regimen for a 30-day period)
Number of subjects: 22
Study: 12117201

Group type: EXPERIMENTAL
Intervention: Sodium chlorite mouthrinse acidified with malic acid
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sodium chlorite mouthrinse acidified with gluconic acid
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinse
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ASC rinse
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sodium chlorite rinse
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 36
Study: 9658884

Group type: EXPERIMENTAL
Intervention: Cisplatin 80 mg/m2 day 1 and etoposide 120 mg/m2 on days 1-3, with vinblastine 5 mg/m2 on days 1 and 3 (in 58 patients)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Cisplatin 80 mg/m2 day 1 and etoposide 120 mg/m2 on days 1-3 (without vinblastine)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide treatment
Number of subjects: 92
Study: 7846096

Group type: EXPERIMENTAL
Intervention: Iron fortification (soup fortified with 20 mg iron and 100 mg vitamin C for 15 weeks on school days)
Number of subjects: 30
Study: 3229833

Group type: EXPERIMENTAL
Intervention: External fixation
Number of subjects: 106

Group type: COMPARATOR
Intervention: Plaster treatment
Number of subjects: 106
Study: 29604402

Group type: COMPARATOR
Intervention: Aquatic exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Land-based exercise
Number of subjects: 40
Study: 27993963

Group type: EXPERIMENTAL
Intervention: SNP rs28714259
Number of subjects: 3431
Study: 25958946

Group type: EXPERIMENTAL
Intervention: Full squat training (n=36)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Combined full squat and sprint training (n=32)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Speed training only (n=34)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Non-training control group (n=20)
Number of subjects: 122
Study: 23890742

Group type: EXPERIMENTAL
Intervention: Gel alcohol-based hand rub (ABHR) formulations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liquid alcohol-based hand rub (ABHR) formulations
Number of subjects: 0
Study: 21205043

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (NNS) for 12 weeks
Number of subjects: 761

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 761
Study: 18461848

Group type: EXPERIMENTAL
Intervention: Hanen Parent Program (experimental treatment group)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Waiting-control group (matched control group)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Parent intervention ratings
Number of subjects: 17
Study: 16476889

Group type: EXPERIMENTAL
Intervention: Retinal residua of retinopathy of prematurity (ROP)
Number of subjects: 247

Group type: COMPARATOR
Intervention: No retinal residua of retinopathy of prematurity (ROP)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Retinal ablation treatment for severe acute-phase ROP
Number of subjects: 247
Study: 14574544

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 32

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 32
Study: 10382135

Group type: EXPERIMENTAL
Intervention: Children with Down syndrome
Number of subjects: 44

Group type: COMPARATOR
Intervention: Controls without mental retardation
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Life events from the past year
Number of subjects: 44
Study: 8882477

Group type: EXPERIMENTAL
Intervention: IFN‐alpha plus cis‐platinum
Number of subjects: 56

Group type: COMPARATOR
Intervention: No antitumor therapy
Number of subjects: 56
Study: 2071558

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6664741

Group type: EXPERIMENTAL
Intervention: (+)-cyanidanol-3 (Catergen) plus prednisolone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (prednisolone only)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: (+)-cyanidanol-3 (Catergen)
Number of subjects: 36
Study: 28816554

Group type: EXPERIMENTAL
Intervention: Bilateral abdominal sacral hysteropexy (BASH)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Classical abdominal sacral hysteropexy (ASH)
Number of subjects: 30
Study: 26472511

Group type: EXPERIMENTAL
Intervention: AutoPulse
Number of subjects: 29

Group type: COMPARATOR
Intervention: LUCAS 2
Number of subjects: 29
Study: 25975423

Group type: EXPERIMENTAL
Intervention: Etravirine 200 mg twice daily + Telaprevir 750 mg every 8 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rilpivirine 25 mg once daily + Telaprevir 750 mg every 8 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telaprevir
Number of subjects: 0
Study: 24669604

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg once daily
Number of subjects: 180

Group type: COMPARATOR
Intervention: Atenolol 50 mg once daily
Number of subjects: 180
Study: 20945743

Group type: EXPERIMENTAL
Intervention: Self-etch adhesive (Adper SE Plus, 3M ESPE)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Etch & rinse adhesive (Adper Single Bond 2, 3M ESPE)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Thermocycling (500 cycles between 5 degrees C and 55 degrees C)
Number of subjects: 56
Study: 18175072

Group type: EXPERIMENTAL
Intervention: Work style intervention (WS and WSPA)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Usual care group (C)
Number of subjects: 466
Study: 16181539

Group type: EXPERIMENTAL
Intervention: Safflower Yellow injection (SYI)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Salvia injection (Control)
Number of subjects: 448
Study: 14625518

Group type: EXPERIMENTAL
Intervention: Ice treatment with light shoulder exercise (ILSE)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Light shoulder exercise (LSE)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Ice treatment (IT)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 7
Study: 10507602

Group type: EXPERIMENTAL
Intervention: Selenium replacement (Se+), sodium selenite for 9 days (535 microg for 3 days, 285 microg for 3 days, and 155 microg for 3 days), then 35 microg per day iv.
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Selenium replacement (Se+), sodium selenite for 9 days, then 35 microg per day iv.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (Se-), received 35 microg of sodium selenite throughout the treatment period.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (Se-), overall mortality.
Number of subjects: 42
Study: 8945145

Group type: EXPERIMENTAL
Intervention: Rehabilitation training
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83